MedPath

Find Therapeutics Doses First Subject in Phase I Trial of FTX-101 for Chronic Optic Neuropathy

• Find Therapeutics initiated a Phase I clinical trial of FTX-101, a potential treatment for chronic optic neuropathy, after receiving FDA approval. • The Phase I trial is a two-part study evaluating the safety, tolerability, and pharmacokinetics of FTX-101 versus placebo in healthy volunteers. • FTX-101 is designed as a remyelinating agent that could restore vision by addressing demyelination in the visual pathways. • The company anticipates releasing data from the Phase I trial in the first half of next year, marking a significant step in developing a novel therapy.

Find Therapeutics, a Canadian biopharmaceutical company, has dosed the first subject in a Phase I clinical trial of its lead compound, FTX-101, as a potential treatment for chronic optic neuropathy. The trial, a two-part study, received approval from the US Food and Drug Administration (FDA) earlier this year and aims to evaluate the safety, tolerability, and pharmacokinetics of FTX-101 compared to placebo in healthy volunteers. This marks a significant milestone for Find Therapeutics in its pursuit of developing innovative therapies for inflammatory autoimmune diseases.
The Phase I trial is structured into two parts: a double-blind, randomized, placebo-controlled, single-ascending dose (SAD) study involving 40 subjects, and a multiple-ascending dose (MAD) study enrolling 24 subjects. Find Therapeutics anticipates releasing data from the trial in the first half of next year.

FTX-101: A Remyelinating Agent

FTX-101 is designed as a remyelinating agent with the potential to restore vision for individuals suffering from chronic optic neuropathy, a condition characterized by demyelination in the visual pathways. Preclinical data have demonstrated strong myelin repair activity, suggesting that FTX-101 could offer a novel approach to treating this debilitating condition.
The therapeutic peptide modulates the Plexin A1 / Neuropilin 1 receptor complex in the brain to promote remyelination.

Management Perspective

"The initiation of this study is a significant milestone for both our company and individuals who suffer from chronic optic neuropathy," said Philippe Douville, CEO of Find Therapeutics. "In this study, we will build on the large body of preclinical evidence demonstrating FTX-101’s effects in models of autoimmune disease. A therapy of this type would represent a major step forward in finding the first treatment to improve the lives of people afflicted with chronic optic neuropathy."

About Find Therapeutics

Founded in 2020, Find Therapeutics is focused on developing next-generation therapies for inflammatory autoimmune diseases. The company has garnered support from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, Investissment Québec, SATT-Conectus, and the University of Strasbourg. Last month, Find Therapeutics raised C$11 million ($8.1 million) in a convertible note financing round to advance FTX-101 into Phase I clinical studies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Tonix Pharmaceuticals' TNX-102 SL Awaits FDA Decision for Fibromyalgia Treatment

Tonix Pharmaceuticals' TNX-102 SL, a non-opioid analgesic, has been assigned an FDA PDUFA goal date of August 15, 2025, for fibromyalgia treatment, potentially offering a new option for millions.
TNX-102 SL demonstrated significant pain reduction and improved sleep quality in Phase 3 trials, addressing key fibromyalgia symptoms with a well-tolerated safety profile.

Tonix Pharmaceuticals Bolsters Leadership as TNX-102 SL Awaits FDA Decision for Fibromyalgia

Tonix Pharmaceuticals has appointed Bradley Raudabaugh as VP of Marketing and Errol Gould as VP of Medical Affairs to support the potential launch of TNX-102 SL.
The FDA is expected to decide on the acceptance of the New Drug Application (NDA) for TNX-102 SL in December 2024, with a potential approval decision in 2025.

Larimar Therapeutics' Nomlabofusp Shows Promise in Friedreich's Ataxia Treatment

Larimar Therapeutics presented positive early clinical trial results for nomlabofusp (CTI-1601) in Friedreich's ataxia (FRDA) patients, highlighting its potential to address frataxin deficiency.
A Phase 2 dose exploration trial demonstrated that nomlabofusp increased frataxin levels in FRDA patients, with the 50-mg dose group showing the most significant improvement over 28 days.

Clarametyx Biosciences Advances CMTX-101 into Phase 2a Trial for Cystic Fibrosis

Clarametyx Biosciences has initiated a Phase 2a trial for CMTX-101, an antibody therapy targeting bacterial biofilms in cystic fibrosis patients with chronic pulmonary infections.
The Phase 2a trial is a double-blind, randomized, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of CMTX-101.

OKYO Pharma Doses First Subject in Phase II Trial of OK-101 for Neuropathic Corneal Pain

OKYO Pharma has dosed the first subject in its Phase II clinical trial of OK-101 for neuropathic corneal pain (NCP).
The trial is a double-masked, randomized, placebo-controlled study involving 48 patients diagnosed with NCP, confirmed via confocal microscopy.

Clarametyx Advances CMTX-101 into Phase 2a for Cystic Fibrosis Lung Infections

Clarametyx Biosciences has initiated the Phase 2a portion of its clinical trial evaluating CMTX-101 for cystic fibrosis (CF)-associated pulmonary infections.
The Phase 2a study aims to enroll up to 41 adults with CF to assess the safety and tolerability of CMTX-101 as an adjunct to standard antibiotics.

Nanoscope Therapeutics to Advance MCO-010 for Stargardt Disease to Phase 3 Trial Following FDA Meeting

Nanoscope Therapeutics' MCO-010 gene therapy is set to advance to a Phase 3 registrational trial for Stargardt Macular Degeneration after a productive meeting with the FDA.
The FDA has provided input on the Phase 3 trial design, which will assess MCO-010's safety and efficacy using best-corrected visual acuity as the primary endpoint.

Neuraptive's NTX-001 Receives FDA Breakthrough Therapy Designation for Peripheral Nerve Injury

NTX-001, a drug-device combination by Neuraptive Therapeutics, has received Breakthrough Therapy Designation from the FDA for treating peripheral nerve injuries requiring repair.
The designation was granted based on promising Phase 2 NEUROFUSE study results, potentially accelerating NTX-001's development and review process.

BlueRock Therapeutics' OpCT-001 Receives FDA Clearance for Phase I/IIa Trial in Primary Photoreceptor Diseases

BlueRock Therapeutics received FDA clearance for its IND application for OpCT-001, an iPSC-derived cell therapy targeting primary photoreceptor diseases.
The Phase I/IIa trial will assess the safety, tolerability, and efficacy of OpCT-001 in restoring vision for individuals with these conditions.

Tonix Pharmaceuticals' Tonmya™ Receives Conditional FDA Acceptance for Fibromyalgia Treatment

Tonix Pharmaceuticals' TNX-102 SL, conditionally named Tonmya™, has received FDA acceptance as a trade name for fibromyalgia management.
Two positive Phase 3 trials demonstrated Tonmya's potential as a novel, first-line treatment option for fibromyalgia, affecting millions in the U.S.

Reference News

[1]
Find Therapeutics dosing subjects in study of FTX-101 for chronic optic neuropathy
clinicaltrialsarena.com · Oct 21, 2024

Find Therapeutics, a Canadian biopharmaceutical company, has initiated a Phase I trial for its lead compound, FTX-101, a...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy